Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

The Therapeutics Goods Administration (TGA) published key discussions from the sixth Human Research Ethics Committee (HREC) and TGA Clinical Trials Discussion Forum.

Source updated: Jul 20, 2026

Primary source: https://www.tga.gov.au/resources/publication/meeting-statements/human-research-ethics-committee-and-tga-clinical-trials-discussion-forum-communique-meeting-6-14-july-2026

PV Impact Brief

Urgency: HighConfidence: high

What changed

Clinical trial sponsors and investigators must review and comply with the updated ISO 14155 standards for medical device clinical safety reporting, especially in light of the discussions regarding N=1 therapeutics and their ethics oversight.

Why it matters

The discussions emphasize the importance of robust ethics oversight and safety monitoring for personalized therapeutics, ensuring that clinical trials adhere to the latest standards.

Action needed

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Relevant for: Regulatory Intelligence LeadPV Quality Lead
Processes impacted: Inspection ReadinessICSR
Owner: Regulatory Intelligence Lead
Review cadence: Review before 2026-07-20.

Policy change details

Document type: Notice
Policy status: final
Publication date: 2026-07-20
Effective date: 2026-07-20
Policy change: TGA published the communique from the sixth HREC/TGA Clinical Trials Discussion Forum held on July 14, 2026. The forum discussed ethics and regulatory oversight for N=1 therapeutics and provided updates on medical device regulations, including ISO 14155 changes and high-risk Clinical Trial Notification (CTN) reviews for the 2025/26 period.

Key changes

Clarification on ethics oversight and regulation for N=1 therapeutics; updates on ISO 14155 (Clinical investigation of medical devices) implementation; outcomes of 2025/26 high-risk CTN reviews.

Affected workflows

Inspection ReadinessICSR

Responsible groups

Clinical SafetyRegulatory AffairsQuality Assurance

PV impact

Clinical trial sponsors and investigators should review the updates on ISO 14155 to ensure compliance with medical device clinical safety reporting standards. The discussions on N=1 research emphasize the need for robust ethics oversight and safety monitoring for personalized therapeutics.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jul 20, 2026

https://www.tga.gov.au/resources/publication/meeting-statements/human-research-ethics-committee-and-tga-clinical-trials-discussion-forum-communique-meeting-6-14-july-2026Updated July 20, 2026

Full briefing

Practical implication

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

The TGA's sixth HREC/TGA Clinical Trials Discussion Forum addressed important updates related to ISO 14155 and the regulatory requirements for N=1 therapeutics. These updates stress the need for clinical trial sponsors to ensure compliance with medical device clinical safety reporting standards, particularly focusing on high-risk Clinical Trial Notification reviews for the 2025/26 period.

What changed: Clinical trial sponsors and investigators must review and comply with the updated ISO 14155 standards for medical device clinical safety reporting, especially in light of the discussions regarding N=1 therapeutics and their ethics oversight.

Why it matters: The discussions emphasize the importance of robust ethics oversight and safety monitoring for personalized therapeutics, ensuring that clinical trials adhere to the latest standards.

Practical implication: Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals #Notice #final #Therapeutic Goods Administration (TGA)#reporting_requirement #policy-change #firecrawl-policy-agent

Related updates for your role

publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead

SOP Impact4 SOPs

ConfidenceHigh

Relevant for: Regulatory Intelligence Lead, QPPV

verifiedRegulatory action: Guidance

Read impact briefarrow_forward

publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead

SOP Impact2 SOPs

ConfidenceHigh

Relevant for: Regulatory Intelligence Lead, Signal Management Lead

verifiedRegulatory action: Agenda

Read impact briefarrow_forward

publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead

SOP Impact1 SOPs

ConfidenceHigh

Relevant for: Regulatory Intelligence Lead, PV Quality Lead

verifiedRegulatory action: Checklist

Read impact briefarrow_forward

publicEuropean Medicines Agency · EU · Updated Jul 15, 2026